药物名称:Ampyra (dalfampridine)适应症:多发性硬化症公司:阿索尔达治疗(Acorda Therapeutics)批准日期:2010年1月22日药品类型:小分子药物简要说明:用于改善多发..
基于28个网页-相关网页
·2,447,543篇论文数据,部分数据来源于NoteExpress
This piece was written by Ron Cohen, the chief executive of Acorda Therapeutics.
FORBES: How The U.S. Can Attract Biotech Firms By Imitating China
Ampyra, a pill approved to help patients with multiple sclerosis walk, has put Acorda Therapeutics in the small club of profitable biotechnology companies.
FORBES: Drug That Helps Multiple Sclerosis Patients Walk May Also Aid Stroke Victims
Cohen founded Acorda Therapeutics, Inc. in 1995.
应用推荐
模块上移
模块下移
不移动